Disease relevance of l-Alanyl-l-glutamine

• There was a significant difference in incidence of mucositis developed in patients receiving placebo compared with those who received L-alanyl-L-glutamine (p = 0.035) [1].
• PURPOSE: We performed this double-blinded, placebo-controlled study to determine the safety and efficacy of L-alanyl-L-glutamine in the prevention of mucositis in patients with head-and-neck cancer [1].
• Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer [1].
• Parenteral L-alanyl-L-glutamine improves 6-month outcome in critically ill patients [2].
• CONCLUSION: L-alanyl-L-glutamine-supplemented TPN improved the infectious morbidity of patients with secondary peritonitis [3].

High impact information on l-Alanyl-l-glutamine

• The purpose of the current study was to investigate whether supplemental l-alanyl-l-glutamine to parenteral nutrition can alter clinical outcome in intensive care unit patients [2].
• Elimination kinetics of L-alanyl-L-glutamine in ICU patients [4].
• The objective of this study was to determine the dose as well as duration of exposure-dependent effects of L-alanyl-L-glutamine, arginine or taurine on polymorphonuclear neutrophil (PMN) free alpha-keto acid profiles and, in a parallel study, on PMN immune functions [5].
• CONCLUSION: In this series of in vitro experiments the dipeptide L-alanyl-L-glutamine exerted almost identical immunostimulatory activities to glutamine alone [6].
• METHODS: In vitro effects of the dipeptide L-alanyl-L-glutamine on different cells of the immune system are assessed and compared to those of glutamine on its own [6].

Anatomical context of l-Alanyl-l-glutamine

• RESULTS: T-lymphocyte proliferation stimulated with mitogens and alloantigens increased significantly and dose-dependently after addition of L-alanyl-L-glutamine or glutamine [6].

Analytical, diagnostic and therapeutic context of l-Alanyl-l-glutamine

• The control group received a conventional amino acid solution (1.5 g amino acids.kg-1.day-1), and the test group received a complete amino acid solution containing the dipeptide L-alanyl-L-glutamine (20 g/L) [7].
• Twenty-nine patients received the CRT schedule and were double-blindly assigned to receive either intravenous L-alanyl-L-glutamine 0.4 g/kg weight/day or an equal volume of saline (placebo) during chemotherapy days [1].
• The effects of administering total parenteral nutrition (TPN) supplemented with the dipeptide of L-alanyl-L-glutamine (Ala-Gln) on gut structure, barrier function, and protein metabolism were investigated in septic rats [8].

References